• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Lighting the Onco-Pipeline, Stem Cell Cancer, and More at Global Cancer Congress, January 28-29, 2008, Tampa

Posted on: Wednesday, 19 September 2007, 09:02 CDT

NEW YORK, Sept. 18 /PRNewswire/ -- iiBIG is pleased to announce the never- before assembly of Global Cancer Experts at the 2008 Global Cancer Congress: Lighting the Onco-Pipeline -- Innovations in Stem Cell, Biomarker, Chemistry & Novel Therapeutic R&D, January 28-29, 2008 in Tampa, Florida. iiBIG is particularly pleased to join forces with our Florida affiliates from University of South Florida, University of Florida, Shands Cancer Center, Scripps Florida, and the other Florida cancer and academic institutes along with our nationally recognized distinguished faculty at this cutting-edge event.

This event will be the torchbearer to the most significant advances in cancer research, new therapies and novel approaches in the "War against Cancer". The program features a 2-track forum, with over 30 speakers, comprising plenary keynotes, lectures, panel sessions, roundtable discussions, interactive conversations with faculty and delegates, and actionable networking opportunities with leaders in various aspects of cancer research.

Distinguished Executive Speaking Faculty: David L. Keefe, M.D. James M. Ingram Professor and Chairman of the Department of Obstetrics and Gynecology University of South Florida George Church, Ph.D. Director of the Center for Computational Genetics, Director of the Department of Genetics Harvard-MIT Division of Health Sciences & Technology and Harvard Medical School, Harvard University William G. Thilly, Sc.D. Professor of Biological Engineering MIT David J. Newman, Phil Sc., Chief, Natural Products Branch National Cancer Institute (NCI)-FCRDC James L. Sherley, M.D., Ph.D. Senior Scientist Regenerative Biology and Cancer Programs Boston Biomedical Research Institute Edward Scott, Ph.D. Director of the UF Program in Stem Cell Biology and Regenerative Medicine University of Florida Gary D. Smith, Ph.D., Associate Professor, Departments of OB/GYN, Physiology, and Urology Director: Reproductive Sciences Program, University of Michigan James D. McChesney, Ph.D., CSO, Natural Products Chemistry Tapestry Pharmaceuticals, Inc. Tomi Sawyer, Ph.D., Senior Director, Department of Chemical Sciences Pfizer Global R&D Michael Nickerson Director Genomic Research Division Transgenomic Labs Dalia Cohen, Ph.D. Executive Vice President, Head of Global Research and Development Rosetta Genomics, Ltd. Gregg B. Fields, Ph.D., Professor and Chair, Department of Chemistry & Biochemistry Florida Atlantic University Chris Liang, Ph.D. Scientific Director I, Translational Research Institute Scripps Florida Marilyn A. Apfel, Ph.D. Co-founder and President xFDA, LLC Julia H. Riley, DVM, MS, Diplomate American College Veterinary Pathologists, Diplomate American Board Toxicology, Heads the Biologics Division, Toxicologist xFDA, LLC Ahsan Awan, JD, MBA, Chief Executive Officers Global CINRG, Inc. Bernard Munos, Ph.D., Advisor, Corporate Strategy Eli Lilly and Company Stephen Chakoff President & CEO CHS Resources LLC Jean-Claude Bystryn, M.D. CEO & CSO NeoVac Glenn Batchelder President and CEO BIND Biosciences, Inc., latest Robert Langer, Ph.D. - MIT, Nanotechnology Company Christopher Milne, D.V.M., M.P.H., J.D. Associate Director Tufts Center for Drug Development Mark Newman, Ph.D. Senior Vice President, Global Research and Development Laboratories Pharmexa-Epimmune AGENDA TOPICS:

Some of the conference topics to be addressed (but are not limited to) include:

-- Integrative BioPharma Oncogenomics Standardizing Genetic Analysis -- Drug Discovery Breakthroughs-Promising Compounds -- Stem Cell Biology & Genetic Integrity -- Interplay between Cancer & Stem Cells -- Immunology -- Micro-Tumor-Environment -- Proteomic Biomarkers - Molecular Diagnostics: Earlier Detection and Customizing Care -- Therapeutic Vaccines Advancements -- Multi-Drug Interaction - Drug Safety -- Cancer Susceptibility, Resistance, and Systemic Changes -- New Drugs Showing Real Promise -- C-Team - Business Collaboration & Alliances between academia, government, industry, foundations, regulatory, and private investment resources - The Real Scenarios! -- Biotech Showcase: Visit with 5 exciting young biotechnology companies* in the cancer marketplace - The Real Light Makers

SPEAKING OPPORTUNITIES: Topic abstracts and speaker profiles will be accepted for consideration.

For more information, please contact Shelley Amster, VP, Pharmaceutical & Life Sciences Conferences, iiBIG, at 978-371-5901 or Shelleya@iibig.com.

SPONSORSHIP OPPORTUNITIES: For information on available sponsorship and exhibiting opportunities, please contact Kellie Swanstrom, VP Business Development, iiBIG, at 973-571-0867 or kellies@iibig.com.

FOR CONFERENCE UPDATES AND REGISTRATION INFORMATION: Please visit: http://www.iibig.com/P0801 Call: 212-300-2523 E-mail: info@iibig.com

iiBIG

CONTACT: Shelley W. Amster, VP, Pharmaceutical & Life Sciences,International Institute for Business Information & Growth - iiBIG,+1-978-371- 5901, Shelleya@iibig.com

Web site: http://www.iibig.com/http://www.iibig.com/P0801

Source: PRNewswire

More News in this Category